<DOC>
	<DOC>NCT00885612</DOC>
	<brief_summary>10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.</brief_summary>
	<brief_title>10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Early Breast Cancer patients Postmenopausal Status patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months Advanced Breast Cancer patients(stage iii, iv) Patients who are hard to be analysed by limitation of chart record according to investigators discretion patients who already have been registered in this study</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>CHD-Risk</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>postmenopausal early breast cancer</keyword>
</DOC>